Osimertinib in Advanced EGFR-Mutant Lung Adenocarcinoma With Asymptomatic Brain Metastases
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study
Neurooncol Adv 2022 Jan 01;4(1)vdab188, N Peled, W Kian, E Inbar, IM Goldstein, M Zemel, O Rotem, AB Rozenblum, H Nechushtan, E Dudnik, D Levin, A Zer, S Keren-Rosenberg, S Yust-Katz, V Fuchs, AA Remilah, I Shelef, LC RoismanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.